On November 11, Liquidia Technologies Inc rose 5.91% in Regular Trading, trading at $54.355 per share, with turnover of $22.3646 million.
The clearest catalyst was a fresh round of analyst follow-through after the company’s third-quarter results, with multiple firms raising price targets while emphasizing strong YUTREPIA commercial traction despite a large litigation-related charge.
After reporting third-quarter revenue of $225.3 million, above the $214.2 million consensus, Liquidia Technologies Inc disclosed YUTREPIA net product sales of $222.7 million, up 31% from the second quarter, and said October patient shipments reached a monthly high. The company posted a loss of $2.64 per share, with the loss largely tied to an about $389.7 million settlement charge related to United Therapeutics. In subsequent analyst actions, BofA raised its target to $54 from $42, Needham raised its target to $66 from $58, and BTIG reiterated Buy with an $87 target, helping support the stock’s intraday move.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments